key articles
Docetaxel and treating metastatic castration-resistant prostate cancer
Wednesday, 1 February 2012- Treatment with docetaxel in combination with prednisone is the standard first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). For patients failing first-line...
Edited by: JV
Detection of prostate cancer with magnetic resonance imaging
Friday, 27 January 2012- H. Aydn and colleagues conducted a study to optimize and predict the most efficient magnetic resonance imaging (MRI) sequences; T1-weighted (T1W), T2-weighted (T2W), dynamic contrast-enhanced (DCE) T1W,...
Edited by: JV
Obesity and its role in prostate cancer screening
Monday, 23 January 2012- Researchers in Family and Community Medicine at Thomas Jefferson University in the US recently found that obesity was linked to higher rates of prostate cancer (PCa) screening across all races/ethnic...
Edited by: JV
Erectile and urinary functions after nerve-sparing radical prostatectomy
Monday, 16 January 2012- The association between baseline functional status and urinary continence recovery after radical prostatectomy remains controversial. G. Gandaglia and colleagues tested the hypothesis that baseline...
Edited by: JV
No evidence of mortality benefit for mass screening in PCa, says PCLO study
Tuesday, 10 January 2012- The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality from...
Edited by: JV
Focal salvage therapy for localised PCa recurrence after external beam radiotherapy
Monday, 9 January 2012- H. S. Ahmed and colleagues conducted a study to evaluate the safety, feasibility, side-effect profile, and proof of concept for focal salvage therapy using high-intensity focused ultrasound (HIFU). They...
Edited by: JV
Conventional vs hypofractionated high-dose intensity-modulated radiotherapy for PCa
Wednesday, 4 January 2012- Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment.
D. Dearnaley and colleagues conducted a pre-planned preliminary safety...
Edited by: JV
Novel Vitamin D analog ZK191784 inhibits prostate cancer cell invasion
Tuesday, 3 January 2012- Low serum levels of 1,25(OH)2D3 (1,25D), have been associated with aggressive biologic behavior of prostate cancer (PCa).
In their study, the results of which were published in the journal Anticancer...
Edited by: JV
Emerging novel therapies for advanced prostate cancer
Tuesday, 27 December 2011- S. Osanto and H. Van Poppel published a review in an online issue of the journal Therapeutic Advances in Urology examining the development and efficacy of novel treatment options for...
Edited by: JV
